Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Synthetic Nucleotide Applications in Therapeutics
4.2.2 Growth in Synthetic Biology
4.3 Market Restraints
4.3.1 Challenges in Developing Long Nucleotide Sequences
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Type
5.1.1 DNA Phosphoramidites
5.1.2 RNA Phosphoramidites
5.1.3 Other Phosphoramidites
5.2 By End-User
5.2.1 Pharmaceutical and Biotechnology Companies
5.2.2 Academic and Research Institutes
5.2.3 Other End-Users
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Rest of the World


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Thermo Fisher Scientific Inc.
6.1.2 Biosynth Ltd
6.1.3 TriLink BioTechnologies
6.1.4 Bioneer Corporation
6.1.5 Hongene Biotech Corporation
6.1.6 Tokyo Chemical Industry Pvt. Ltd.
6.1.7 Danaher Corporation
6.1.8 Creative Biolabs, Inc.
6.1.9 PolyOrg, Inc.
6.1.10 Lumiprobe Corporation
6.1.11 QIAGEN N.V.
6.1.12 BOC Sciences


7 MARKET OPPORTUNITIES AND FUTURE TRENDS